• Je něco špatně v tomto záznamu ?

Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry

Z. Hruskova, VS. Stel, D. Jayne, K. Aasarød, J. De Meester, A. Ekstrand, K. Eller, JG. Heaf, A. Hoitsma, C. Martos Jimenéz, P. Ravani, C. Wanner, V. Tesar, KJ. Jager,

. 2015 ; 66 (4) : 613-20. [pub] 20150512

Jazyk angličtina Země Spojené státy americké

Typ dokumentu hodnotící studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000143

BACKGROUND: This study describes the incidence and outcomes of European patients requiring renal replacement therapy (RRT) for kidney failure due to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 12 renal registries providing individual RRT patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated. PREDICTOR: Cause of primary kidney disease: AAV (ie, granulomatosis with polyangiitis [Wegener] and microscopic polyangiitis) versus 3 separate matched control groups without AAV: (1) primary glomerulonephritis, (2) diabetes mellitus, and (3) disease other than diabetes mellitus as the cause of primary kidney disease, including glomerulonephritis (termed "nondiabetes"). OUTCOMES: Incidence, causes of death, and survival. MEASUREMENTS: ERA-EDTA primary renal disease codes. RESULTS: 2,511 patients with AAV (1,755, granulomatosis with polyangiitis; 756, microscopic polyangiitis) were identified, representing an incidence of 1.05 per million population (pmp) for granulomatosis with polyangiitis (predominating in Northern Europe) and 0.45 pmp for microscopic polyangiitis (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) patients with vasculitis. The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in patients with vasculitis. Survival on RRT after day 91 did not differ between AAV and matched nondiabetes patients. Patient and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes patients (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively). LIMITATIONS: No data for extrarenal manifestations, treatment, and relapses. CONCLUSIONS: Geographical differences in the incidence of RRT for kidney failure due to granulomatosis with polyangiitis and microscopic polyangiitis copied their distribution in the general population. Overall survival on RRT after day 91 for patients with AAV was similar to that for patients with nondiabetes diagnoses. Our results suggest that patients with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000143
003      
CZ-PrNML
005      
20180625073851.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.ajkd.2015.03.025 $2 doi
035    __
$a (PubMed)25975963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hruskova, Zdenka $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Electronic address: zd.hruskova@gmail.com.
245    10
$a Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry / $c Z. Hruskova, VS. Stel, D. Jayne, K. Aasarød, J. De Meester, A. Ekstrand, K. Eller, JG. Heaf, A. Hoitsma, C. Martos Jimenéz, P. Ravani, C. Wanner, V. Tesar, KJ. Jager,
520    9_
$a BACKGROUND: This study describes the incidence and outcomes of European patients requiring renal replacement therapy (RRT) for kidney failure due to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 12 renal registries providing individual RRT patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated. PREDICTOR: Cause of primary kidney disease: AAV (ie, granulomatosis with polyangiitis [Wegener] and microscopic polyangiitis) versus 3 separate matched control groups without AAV: (1) primary glomerulonephritis, (2) diabetes mellitus, and (3) disease other than diabetes mellitus as the cause of primary kidney disease, including glomerulonephritis (termed "nondiabetes"). OUTCOMES: Incidence, causes of death, and survival. MEASUREMENTS: ERA-EDTA primary renal disease codes. RESULTS: 2,511 patients with AAV (1,755, granulomatosis with polyangiitis; 756, microscopic polyangiitis) were identified, representing an incidence of 1.05 per million population (pmp) for granulomatosis with polyangiitis (predominating in Northern Europe) and 0.45 pmp for microscopic polyangiitis (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) patients with vasculitis. The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in patients with vasculitis. Survival on RRT after day 91 did not differ between AAV and matched nondiabetes patients. Patient and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes patients (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively). LIMITATIONS: No data for extrarenal manifestations, treatment, and relapses. CONCLUSIONS: Geographical differences in the incidence of RRT for kidney failure due to granulomatosis with polyangiitis and microscopic polyangiitis copied their distribution in the general population. Overall survival on RRT after day 91 for patients with AAV was similar to that for patients with nondiabetes diagnoses. Our results suggest that patients with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.
650    _2
$a dospělí $7 D000328
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a příčina smrti $7 D002423
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a granulomatóza s polyangiitidou $x diagnóza $x mortalita $x terapie $7 D014890
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a chronické selhání ledvin $x diagnóza $x mortalita $x terapie $7 D007676
650    _2
$a vyšetření funkce ledvin $7 D007677
650    _2
$a transplantace ledvin $x metody $x mortalita $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikroskopická polyangiitida $x diagnóza $x mortalita $x terapie $7 D055953
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    12
$a registrace $7 D012042
650    _2
$a dialýza ledvin $x metody $x mortalita $7 D006435
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a společnosti lékařské $7 D012955
650    _2
$a míra přežití $7 D015996
651    _2
$a Evropa $7 D005060
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stel, Vianda S $u ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam, the Netherlands.
700    1_
$a Jayne, David $u Department of Medicine, University of Cambridge, Cambridge, United Kingdom. $7 xx0225517
700    1_
$a Aasarød, Knut $u Department of Renal Medicine, St Olav's University Hospital, Trondheim, Norway. $7 gn_A_00000116
700    1_
$a De Meester, Johan $u Department of Nephrology, Dialysis and Hypertension, AZ Nikolaas, Sint-Niklaas, Belgium.
700    1_
$a Ekstrand, Agneta $u Division of Nephrology, Department of Medicine, Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Eller, Kathrin $u Clinical Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
700    1_
$a Heaf, James G $u Department of Nephrology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Hoitsma, Andries $u Division of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands.
700    1_
$a Martos Jimenéz, Carmen $u Centre for Public Health Research (CSISP-FISABIO), Valencia, Spain.
700    1_
$a Ravani, Pietro $u Department of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Canada.
700    1_
$a Wanner, Christoph $u Division of Nephrology, Department of Medicine, University Hospital, Würzburg, Germany.
700    1_
$a Tesar, Vladimir $u Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jager, Kitty J $u ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam, the Netherlands.
773    0_
$w MED00000258 $t American journal of kidney diseases the official journal of the National Kidney Foundation $x 1523-6838 $g Roč. 66, č. 4 (2015), s. 613-20
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25975963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20180625074121 $b ABA008
999    __
$a ok $b bmc $g 1102424 $s 924349
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 66 $c 4 $d 613-20 $e 20150512 $i 1523-6838 $m American journal of kidney diseases $n Am J Kidney Dis $x MED00000258
LZP    __
$a Pubmed-20160108
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace